Journal
EUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume 49, Issue -, Pages 23-29Publisher
ELSEVIER
DOI: 10.1016/j.ejim.2018.01.009
Keywords
Endocannabinoids; CB1 receptor; Obesity; NAFLD; Chronic kidney disease; Bone remodeling
Categories
Funding
- Israel Science Foundation [617/14]
- ERC-StG grant [676841]
- European Research Council (ERC) [676841] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Endocannabinoids (eCBs) are internal lipid mediators recognized by the cannabinoid-1 and -2 receptors (CB1R and CB2R, respectively), which also mediate the different physiological effects of marijuana. The endocannabinoid system, consisting of eCBs, their receptors, and the enzymes involved in their biosynthesis and degradation, is present in a vast number of peripheral organs. In this review we describe the role of the eCB/CB1R system in modulating the metabolism in several peripheral organs. We assess how eCBs, via activating the CB1R, contribute to obesity and regulate food intake. In addition, we describe their roles in modulating liver and kidney functions, as well as bone remodeling and mass. Special importance is given to emphasizing the efficacy of the recently developed peripherally restricted CB1R antagonists, which were pre-clinically tested in the management of energy homeostasis, and in ameliorating both obesity-and diabetes-induced metabolic complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available